Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment Market By Treatment Type (Chemotherapy, Immunotherapy), Therapy (First-Line Therapy, Second-line Therapy), & Region for 2024-2031

Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment Market Valuation – 2024-2031

The rising incidence of NHL and CLL worldwide is significantly boosting the demand for effective treatment options is propelling the adoption of non-hodgkin’s lymphoma and chronic lymphoma treatment. Innovations in targeted therapies, including monoclonal antibodies and CAR T-cell therapy is driving the market size surpass USD 9.26 Billion valued in 2024 to reach a valuation of around USD 17.79 Billion by 2031.

In addition to this, advances in diagnostic methods are enabling earlier and more accurate detection of these lymphomas is spurring up the adoption of non-hodgkin’s lymphoma and chronic lymphoma treatment. Increased government funding for cancer research and favorable reimbursement policies are enabling the market to grow at a CAGR of  8.5% from 2024 to 2031.

Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment MarketDefinition/ Overview

Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) are types of cancers affecting the lymphatic system and the blood, respectively. NHL includes a diverse group of blood cancers originating in the lymphocytes, a type of white blood cell. CLL is a type of leukemia that starts in the bone marrow and affects lymphocytes, primarily impacting older adults and typically growing slowly over time.

The treatment for NHL and CLL encompasses various approaches such as chemotherapy, radiation therapy, targeted therapy, immunotherapy, and stem cell transplant. Chemotherapy and radiation aim to kill or shrink cancer cells, while targeted therapies focus on specific molecules involved in cancer growth. Immunotherapies, including CAR T-cell therapy, enhance the immune system’s ability to fight cancer. Stem cell transplants are used to replace diseased bone marrow with healthy cells, and in rare cases, surgery may be employed to remove localized tumors.

The future of NHL and CLL treatment looks promising with advancements in personalized medicine, next-generation immunotherapies, and combination therapies. Personalized medicine aims to tailor treatments based on the genetic profile of individual tumors, leading to more effective and less toxic options.

How will Advancements in Targeted Therapies And Immunotherapies Increase Adoption of Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment?

Rising incidence rates are a key driver of the non-hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market. According to the American Cancer Society, an estimated 80,470 new cases of NHL were expected in the US in 2023. The global incidence of NHL increased by approximately 45% between 1990 and 2017, as reported in a study published in The Lancet Haematology. This growing patient population has spurred increased investment in research and development of novel therapies.

Advancements in targeted therapies and immunotherapies have revolutionized treatment approaches. The FDA approval of CAR T-cell therapies, such as Yescarta and Kymriah, for certain types of NHL has opened new avenues for treatment-resistant patients. In February 2024, Roche announced positive results from their phase III POLARIX study, showing that Polivy plus R-CHP significantly improved progression-free survival compared to the standard of care in previously untreated diffuse large B-cell lymphoma patients.

The aging global population is another significant market driver, as NHL and CLL risk increases with age. The World Health Organization projects that by 2030, 1 in 6 people in the world will be aged 60 years or over. This demographic shift is expected to increase the demand for lymphoma treatments. Additionally, the rise of personalized medicine approaches, supported by advancements in genomic profiling, is enabling more tailored treatment strategies, potentially improving outcomes and driving market growth.

Will Cybersecurity and Costs of Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment Restrain Its Application?

The high cost of advanced therapies like CAR T-cell therapy, targeted therapies, and immunotherapies in the non-hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market, particularly in low- and middle-income countries, can limit access for many patients, despite their efficacy, and hinder widespread adoption of these innovative treatments.

Another significant restraint is the potential for severe side effects and complications associated with current treatment modalities. Chemotherapy and radiation therapy, while effective, can cause a range of adverse effects, including immune suppression, fatigue, and organ damage. Advanced therapies like CAR T-cell therapy and stem cell transplants carry risks of serious complications such as cytokine release syndrome and graft-versus-host disease. These side effects can limit patient eligibility and adherence to treatment plans, impacting overall treatment outcomes.

Limited access to advanced diagnostic tools and treatments, particularly in developing regions, poses a major challenge. There is also a lack of awareness and understanding about NHL and CLL among patients and healthcare providers, leading to delayed diagnoses and suboptimal treatment. Inadequate healthcare infrastructure, shortage of specialized medical professionals, and insufficient funding for cancer care in these regions further exacerbate the issue, preventing many patients from receiving timely and effective treatment.

Category-Wise Acumens

Will Rise in Adoption of Stem Cell Transplantation (SCT) Drive Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment Market?

Stem Cell Transplantation (SCT) is emerging as a leading treatment option for non-hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). According to the Center for International Blood and Marrow Transplant Research, the number of autologous stem cell transplants for NHL increased by 35% between 2010 and 2020. The National Marrow Donor Program reported that as of 2023, approximately 22,000 allogeneic transplants are performed annually worldwide for various hematologic malignancies, including NHL and CLL. This growth is driven by improved transplant techniques, reduced complications, and expanded donor pools.

Advancements in SCT protocols have significantly improved outcomes. A study published in the New England Journal of Medicine in February 2024 demonstrated that CAR T-cell therapy followed by autologous SCT increased 3-year progression-free survival rates by 40% compared to standard chemotherapy in relapsed/refractory large B-cell lymphoma patients. In March 2024, Novartis announced promising results from their phase II ELARA trial, showing that Kymriah (tisagenlecleucel) followed by SCT achieved a complete response rate of 85% in follicular lymphoma patients.

The expanding use of haploidentical transplants has broadened SCT accessibility. The National Cancer Institute reported a 150% increase in haploidentical transplants for lymphoma between 2015 and 2023. In April 2024, Gamida Cell received FDA approval for Omisirge, a cell therapy product designed to enhance engraftment in patients undergoing allogeneic SCT. This approval is expected to further boost the adoption of SCT in NHL and CLL treatment, potentially increasing market growth by 15-20% over the next five years.

Which Factors Contributing to Palliative Care Segment’s Dominance in Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment Market?

Palliative care is becoming increasingly crucial in non-hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment, significantly impacting market dynamics. According to the National Hospice and Palliative Care Organization, referrals for palliative care in hematologic malignancies increased by 40% between 2018 and 2023. A study published in the Journal of Clinical Oncology in January 2024 reported that early integration of palliative care in NHL treatment improved quality of life scores by 30% and reduced hospital readmissions by 25%. This growing recognition of palliative care’s value has led to increased investment in specialized programs and services.

The expansion of home-based palliative care services has been a key market driver. The Centers for Medicare & Medicaid Services reported a 60% increase in reimbursements for home-based palliative care for NHL and CLL patients from 2020 to 2023. In March 2024, Amedisys, a leading home health care provider, announced a partnership with the Leukemia & Lymphoma Society to launch a nationwide home-based palliative care program specifically tailored for lymphoma patients. This initiative aims to improve access to specialized care and is projected to serve over 10,000 patients in its first year.

Technological advancements in symptom management have further propelled the palliative care market. The FDA’s approval of novel pain management devices and medications specifically for cancer-related pain has expanded treatment options. In February 2024, Johnson & Johnson unveiled a new wearable device for continuous pain monitoring in lymphoma patients, which integrates with telehealth platforms for real-time palliative care interventions. Additionally, Pfizer announced positive results from a phase III trial of a new opioid formulation designed to minimize side effects in hematologic cancer patients, potentially improving the quality of life for those receiving palliative care.

Gain Access into Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment Market Report Methodology

Country/Region-wise Acumens

Will Strong Presence of Key Pharmaceutical Companies in North America Mature Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment Market?

North America dominating the non-hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market, driven by high incidence rates and advanced healthcare infrastructure. According to the National Cancer Institute, an estimated 80,470 new cases of NHL were diagnosed in the United States in 2023, representing about 4% of all new cancer cases. The American Cancer Society reported that the 5-year relative survival rate for NHL has improved to 73% as of 2024, up from 69% in 2014. This improvement is largely attributed to the region’s early adoption of innovative therapies and significant investment in research and development.

The United States dominates the North American market, bolstered by robust reimbursement policies and a strong presence of key pharmaceutical companies. The Centers for Medicare & Medicaid Services reported a 25% increase in spending on NHL and CLL treatments between 2020 and 2023. In February 2024, Gilead Sciences announced positive results from their phase III ZUMA-7 trial, demonstrating that CAR T-cell therapy Yescarta significantly improved event-free survival compared to standard of care in relapsed or refractory large B-cell lymphoma patients. This breakthrough is expected to further solidify North America’s market leadership.

Canada is also contributing significantly to the region’s dominance. Health Canada reported a 15% increase in approved clinical trials for NHL and CLL treatments from 2022 to 2024. In March 2024, Canadian biotech company BioVaxys Technology Corp. announced a partnership with the Princess Margaret Cancer Centre to develop a novel immunotherapy for follicular lymphoma. Additionally, the Canadian government’s recent allocation of $500 million for cancer research over the next five years, announced in April 2024, is expected to further boost innovation in lymphoma treatments, potentially expanding North America’s market share by an additional 3-5% by 2026.

Will Rising Advanced Therapies in Asia Pacific Drive the Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment Market Growth?

The Asia Pacific region is experiencing rapid growth in the non-hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market, driven by increasing incidence rates and improving healthcare infrastructure. According to the World Health Organization, the incidence of NHL in Southeast Asia increased by 30% between 2015 and 2023. China’s National Cancer Center reported a 25% rise in NHL cases from 2018 to 2023, with an estimated 88,090 new cases in 2023. This growing patient population, coupled with rising healthcare expenditure in countries like India and China, is fueling market expansion.

Improved access to advanced therapies is accelerating market growth. Japan’s Pharmaceuticals and Medical Devices Agency approved 15 new treatments for NHL and CLL between 2020 and 2024, a 50% increase from the previous five-year period. In February 2024, BeiGene announced positive results from their phase III ALPINE study, showing that Brukinsa (zanubrutinib) demonstrated superior progression-free survival compared to ibrutinib in CLL patients. This development is expected to significantly impact the Asian market, potentially increasing BeiGene’s market share by 10-15% over the next two years.

Competitive Landscape

The non-hodgkin’s lymphoma and chronic lymphoma treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the non-hodgkin’s lymphoma and chronic lymphoma treatment market include

• Roche Holding AG
• AbbVie, Inc.
• Gilead Sciences, Inc.
• Novartis International AG
• Bristol-Myers Squibb Company
• Amgen, Inc.
• Johnson & Johnson
• AstraZeneca PLC
• Pfizer, Inc.
• Celgene Corporation
• Merck & Co., Inc.
• Eli Lilly and Company
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Seagen, Inc.
• Astellas Pharma, Inc.
• Bayer AG
• Incyte Corporation
• Kite Pharma (a Gilead Company)
• BeiGene, Ltd.

Latest Developments

• In February 2024, BeiGene’s Brukinsa (zanubrutinib) received FDA approval for the treatment of chronic lymphocytic leukemia, based on superior efficacy demonstrated in the ALPINE study compared to ibrutinib.
• In May 2024, Gilead Sciences launched a global phase III trial evaluating a novel bispecific antibody, GS-3583, in combination with standard of care for previously untreated diffuse large B-cell lymphoma patients.

Report Scope

Non-Hodgkin’s Lymphoma And Chronic Lymphoma Treatment Market, By Category

Treatment Type

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Stem Cell Transplantation

Therapy

• First-Line Therapy
• Second-line Therapy
• Maintenance Therapy
• Palliative Care

Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factorsProvision of market value (USD Billion) data for each segment and sub-segmentIndicates the region and segment that is expected to witness the fastest growth as well as to dominate the marketAnalysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each regionCompetitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiledExtensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market playersThe current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regionsIncludes an in-depth analysis of the market of various perspectives through Porter’s five forces analysisProvides insight into the market through Value ChainMarket dynamics scenario, along with growth opportunities of the market in the years to come6-month post-sales analyst support

Customization of the Report

In case of any  please connect with our sales team, who will ensure that your requirements are met.